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ABBREVIATED TITLE PAGE 
Manuscript title: Prevalence and distribution of atherosclerosis in a low to 
intermediate risk population:  assessment by whole body MR angiography. 
 
Manuscript type: Original Research. 
 
 
Implications for Patient Care:  
1. Whole body magnetic resonance angiography is feasible at a population level 
and detects early atherosclerotic disease missed by modalities assessing 
single vascular sites.   
2. Early atherosclerotic disease detected by whole body magnetic resonance 
angiography is scattered throughout the body.  Thus early disease would be 
missed by evaluating only a single vascular territory. 
 
 
Summary statement: Whole body magnetic resonance angiography identifies early 
vascular disease at a population level.  Its systematic nature allows detection of early 
atherosclerotic disease that may be missed by assessing single vascular sites.  
  
 
 
ABSTRACT 
 
Purpose: 
To quantify the burden and distribution of asymptomatic atherosclerosis in a 
population with a low-intermediate risk of cardiovascular disease. 
Materials and Methods: 
Between June 2008 and February 2013 1,528 participants with <20% 10-year risk of 
cardiovascular disease were prospectively enrolled.  They underwent whole body 
magnetic resonance angiography (WBMRA) at 3T using a two injection, 4 station 
acquisition technique. Thirty-one arterial segments were scored according to 
maximum stenosis. Scores were summed and normalized for the number of 
assessable arterial segments to provide a standardized atheroma score (SAS). 
Multiple linear regression was performed to assess effects of risk factors on 
atheroma burden.  
Results: 
1,513 participants (577/1513 (37.9%) male, median 53.5 years old (Range 40-83)) 
completed the study protocol. Of 46,903 potentially analyzable segments, 46,601 
(99.4%) were interpretable. 2,468 segments (5%) demonstrated stenoses, of which 
1649 (3.5%) were <50%, and 484 (1.0%) were ≥50% stenosis. Vascular stenoses 
were distributed throughout the body with no localized distribution. 747 (49.4%) 
participants had at least one stenotic vessel, and 408 (27.0%) participants had 
multiple stenotic vessels. On multivariable linear regression, SAS correlated with age 
(B=3.4, 95% CI 2.61-4.20), heart rate (B=1.23, 95%CI 0.51-1.95), systolic blood 
pressure (B=0.02, 95% CI 0.01-0.03), smoking status (B=0.79, 95% CI 0.44-1.15) 
and socioeconomic status (B=-0.06 (95%CI -0.10 - -0.02) (p<0.01 for all). 
 
 
Conclusion: 
Whole body magnetic resonance angiography identifies early vascular disease at a 
population level. While on a per-vessel level disease prevalence is low, on a per-
participant level, vascular disease is common even in this low-intermediate risk 
cohort. 
  
 
 
MAIN BODY 
Introduction 
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity 
causing 30.8% of all deaths in the US (1). Atheroma develops over a period of time 
and subclinical disease is present for some time before clinical symptoms are 
noticed (2). Current techniques for early plaque detection such as coronary calcium 
scoring and carotid intima-media thickness (CIMT) are all currently limited to one 
cardiovascular territory. Atherosclerosis is, however, a systemic disease affecting the 
entire body, thus early atherosclerosis may be missed by single site techniques. 
Global efforts have been focused on both the ability to use imaging to better 
understand the interaction between genetics and early disease such as in the UK 
Biobank imaging substudy which is in the process of scanning 100,000 out of the 
500,000 originally enrolled in the overarching UK biobank study (3), but also in the 
role of whole body imaging as a screening technique at a population level such as in 
the SHIP (Study of Health in Pomerania) study (4). Contrast-enhanced whole body 
magnetic resonance angiography (WBMRA) is one such technique allowing a 
systematic approach to imaging the entire vascular tree to stratify and quantify 
cardiovascular disease (5-11). Magnetic resonance (MR) angiography has been 
shown to be highly accurate in detection of stenosis when compared with invasive 
angiography (12,13), and previous reports have shown global atheroma burden 
quantified using WBMRA to correlate with cardiovascular risk, the presence of 
coronary artery disease and both single and recurrent cardiovascular events (14-18). 
However, to date, WBMRA has not been examined in a large population free from 
clinically apparent CVD. 
 
 
We hypothesis that: early disease would be present even in those considered to be 
at low-intermediate risk for CVD. Therefore, our study’s purpose was to quantify the 
burden and distribution of asymptomatic atherosclerosis in a population with a low-
intermediate risk of cardiovascular disease. 
 
Materials and Methods 
Our study (TAyside SCreening FOR Cardiac Events or TASCFORCE) is a 
prospective normal volunteer cardiovascular risk screening study (ISRCTN number: 
ISRCTN38976321). Our protocol was approved by the Tayside Committee of 
Medical Research Ethics. Written informed consent was obtained from each 
participant prior to enrollment in our study. 
Men and women aged 40 years or older living in Tayside or Fife, Scotland, were 
eligible for participation. Recruitment was performed using a random cluster 
sampling pattern with pre planned periodic sample review to ensure the recruited 
population accurately represented the sex, age and socioeconomic status of the 
Tayside population from which it was drawn.  When deviations from this occurred 
recruitment strategies were modified to target those groups who were under-
represented.  Exclusion criteria were: known atherosclerotic disease; predicted 
increased risk of CVD requiring statin treatment according to the Scottish 
Intercollegiate Guideline Network, Guideline 97 (17) (risk increased ≥20% in 10 
years); blood pressure (BP) greater than 145/90mmHg; diabetes; inability to give 
informed consent. To produce a cohort able to participate in a potential future statin 
intervention study, those with a primary muscle disease, biochemical abnormalities, 
other serious illness or abnormalities that may compromise the participant's safety 
taking a statin, known alcohol abuse, pregnancy; breast-feeding; women of child-
 
 
bearing potential not using adequate contraception or participation in a clinical trial 
other than observational trials or registries concurrently or within 30 days prior to 
screening were also excluded. These criteria were examined at visit 1, during which 
blood was collected for cholesterol measurement in non-fasting conditions (random 
sample), to allow calculation of both the cardiovascular risk score and brain 
natriuretic peptide (BNP). Those with diabetes were excluded from the study.  If the 
random blood glucose serum level was >7mmol/l they were excluded from the study 
and referred to their family practitioner for further work-up.  Smoking status was self 
classified by participants as never smoker, ex smoker or current smoker. The 
Scottish index of multiple deprivation was calculated based on the home address of 
the participants used for the calculation of each individual’s ASSIGN (ASsessing 
cardiovascular risk using Scottish intercollegiate guideline network guidelines) 
score.(19)All participants who took part in the imaging substudy underwent a MR 
imaging scan at visit 2.  
 
MRI acquisition technique 
Cardiac MR and WBMRA were performed at a single center. The imaging protocol 
for TASCFORCE and the results of the cardiac analysis of 1,515 participants have 
been previously described (20-23).  This is the first report of the vascular analysis for 
our TASCFORCE imaging study. The scans were performed in an integrated 
examination on a 32-channel 3T Magnetom Trio (Siemens, Munich, Germany). For 
the WBMRA, surface coils covering the whole body were placed on each of our 
study’s participants. Unenhanced MR angiography “mask” data were acquired for the 
thoracic and neck stations and the calf station using a 3D TurboFLASH sequence. 
10 ml of 0.5 mmol/ml gadoterate meglumine (Dotarem, Guerbet, France) followed by 
 
 
20 ml 0.9% sodium chloride were then injected at a rate of 1.5 ml/s. The contrast-
enhanced acquisition for station 1 (thoracic and neck vessels) commenced when the 
contrast agent attained the superior-most aspect at the top of the aortic arch. Post-
contrast data for station 4 (the calves) were acquired immediately after completion of 
station 1, and these were acquired three times consecutively to optimize capture of 
peak arterial enhancement in both limbs. Following a delay, a 3D Turbo-FLASH 
“mask” data were acquired for station 2 (abdominopelvic vessels) and station 3 
(thigh vessels). The second dose of 15ml of gadoterate meglumine was infused at 
1.5 ml/s followed by a 20 ml normal saline flush. Acquisition was triggered when the 
bolus could be seen arriving in the abdominal aorta. Post-contrast data for station 3 
were acquired immediately after completion of the station 2 sequence. The mean 
time between first and second contrast agent injections was 19 minutes, with a total 
imaging time of 50 minutes.  
 
WMBRA scoring technique 
The MR angiography images were independently analyzed by one of four observers 
blinded to the clinical characteristics of the study participant (GH 20 years vascular 
radiology experience, RW 5 years vascular radiology experience, JWM 4 years 
vascular radiology experience, MAL 2 years vascular radiology experience) using 
Carestream PACS (v10.1, Rochester, New York, USA) using the original source 
images, subtracted multiplanar reconstructions and maximum intensity projections. 
The arterial tree was divided into 31 segments: right and left internal carotid arteries, 
right and left vertebral arteries, right and left common carotid arteries, innominate 
artery, right and left subclavian arteries, aortic arch, thoracic aorta, abdominal aorta, 
celiac trunk, superior mesenteric artery, inferior mesenteric artery, right and left renal 
 
 
arteries, right and left iliac arteries, right and left femoral arteries (incorporating 
common and superficial femoral artery), right and left profunda femoris arteries, right 
and left popliteal arteries, right and left anterior tibial arteries, right and left peroneal 
arteries, and right and left posterior tibial arteries. Each arterial segment was visually 
assessed for the region of greatest stenosis. The severity of the stenosis was scored 
by visually comparing the degree of stenosis compared to the normal diameter of an 
unaffected part of the vessel on tangential longitudinal views of the vessel using 
multiplanar reformating. Each segment was coded 0-9 according to the maximum 
stenosis present within the vessel (codes 0-4) and the presence of aneurysmal 
dilation (codes 5-9) as per Table 1. For instance a code of zero would represent a 
completely normal vessel with neither stenosis nor aneurysm, a code of 3 would 
indicate that the tightest stenosis within the vessel was in the magnitude of 71-99%, 
and a code 9 would be an aneurysmal occluded vessel. This code was then 
converted to a final vessel score as per Table 1.  
Arterial segments which were not visualized with sufficient clarity for grading of the 
degree of stenosis were recorded as unassessable. To account for this, the final 
score was divided by the number of segments which had been successfully analyzed 
(n), and then calculated as a percentage of the maximum possible stenosis score 
(see equation below) to produce a ‘standardized atheroma score’ (SAS) (17). The 
reproducibility of this scoring technique has been previously reported based on the 
analysis of 48 scans randomly selected by the trial statistician with excellent intra- 
and inter-observer agreement (20). See Figure 2 for examples of WBMRAs 
acquired. 
All scans were also separately reviewed and reported for incidental findings by a 
radiologist (GH or JWM) shortly after being acquired. 
 
 
 
Statistical analysis 
Data are expressed as mean ± SD for continuous variables, median (range) for 
ordinal variables and number of participants (%) for nominal variables. Normality 
tests were performed; if the test failed, when possible, standard transformations 
were used to generate a Gaussian distribution. The statistical analysis plan was 
predetermined before data analyses. To compare those who underwent an MR 
imaging scan with those who did not, a t-test was used for normally distributed 
variables, Mann-Whitney test for skewed and ranked variables and Chi-square test 
for binomial variables to test the null hypothesis that samples originate from the 
same source. Univariable linear regression was used to assess for correlation 
between the SAS and baseline demographic data in both the whole population and 
male and females separately.  A multivariable linear regression was performed on 
the whole population with sex accounted for within the model as a dichotomous 
nominal variable.  The model included age, gender, smoking status, systolic BP, 
diastolic BP, heart rate, total cholesterol, high density lipoprotein cholesterol, LDL 
cholesterol, triglycerides, body mass index, waist circumference, family history of 
cardiovascular disease, SIMD decile and BNP level. Those variables with a 
positively skewed distribution were log transformed to create a near normal 
distribution.  Statistical analyses were performed using computer software R 3.1 (R 
Foundation for Statistical Computing, Vienna, Austria) and SPSS v 21 (IBM, New 
York)). A 2-sided p value of <0.05 was taken to be significant for analyses.  
 
Results 
 
 
4423 participants were recruited to our TASCFORCE study. Figure 1 summarizes 
the flow of these participants through our TASCFORCE study. Of the 2047 
participants eligible for and offered an MR imaging scan, 373 (18.2%) did not give 
consent to undergo a scan and 14 (0.6%) failed to attend for their MR imaging scan 
appointment. 101 participants (4.9%) were not scanned due to claustrophobia 
(n=83), large body habitus (n=3), problems with intravenous cannulation (13) or 
other technical issues (n=2). 34 (1.7%) were considered unsafe to undergo a scan 
due to the presence of metalwork. 74.6% (1528/2047 of those invited) completed or 
partially completed the scan protocol with 15 (1.0%) excluded due to missing or 
incomplete data, leaving 1,513 in the final analysis. The characteristics of those who 
did not complete scanning and those who did have a scan are summarized in table 
2.  
 
Incidental findings on MR imaging scan 
34 participants (2.2% of 1528 participants scanned) had incidental findings on their 
MR imaging scan which were considered clinically notable by the reviewing 
radiologists. These included myocardial infarction (n=3); structural cardiac 
abnormalities (n=7) including cardiomyopathies, septal defects and enlargement of 
cardiac chambers; benign mass (n=10); malignant mass (n=1); peripheral artery 
abnormality (n=6) including substantial occlusions or aneurysms; noteworthy 
anatomical variant (n=5); and others (n=2). These resulted in 16 participants 
undergoing further downstream testing and 32 undergoing additional review by our 
study doctor (n=6), their family physician (n=9) or a hospital specialist (n=17) (See 
supplemental tables S1 and S2 for an overview of the incidental findings and activity 
resulting from them).  Other than these described abnormalities where further follow-
 
 
up/intervention were deemed necessary, the findings of the WBMRA were blinded to 
the patient and their clinicians so as to allow accurate longitudinal assessment of its 
implications in addition to the lack of proof of intervention currently based on these 
findings. 
 
WBMRA results 
1513 participants were included in the final analysis. A breakdown of the number of 
arterial segments according to the degrees of luminal stenosis and other 
abnormalities is illustrated graphically in figure 3. The presence and degree of 
abnormality is given for each of the 31 segments analyzed per particpant to show the 
distribution of abnormality. The vast majority of segments (44435/46903, 94.7%) 
were assessed as normal. Of the vessel segments assessed to have some stenosis 
or aneurysm, 3.5%(1649/46903) had mild stenosis (<50%), and 1.0% (484/46903) 
exhibited ≥50% stenosis. 40 arterial segments were aneurysmal although only 7 of 
these were associated with a stenosis. Therefore, the greatest contribution towards 
the SASs greater than 0 came from stenoses.  
The coeliac trunk was disproportionately affected by stenosis, in addition to which it 
was also the vessel with the poorest inter-observer repeatability (Fleiss' kappa=0.66 
versus ≥ 0.81 in all the other districts) (20). As this stenosis could potentially be 
either atherosclerotic or secondary to median arcuate ligament compression, the 
celiac trunk was excluded from the calculation of the SAS score and subsequent 
analysis. 
Despite 94.7% of vessels being normal, 747 (49.4%) out of 1513 participants had at 
least one stenotic vessel, and 408 participants (27.0%) had stenoses involving 
multiple arterial segments. At an individual participant level, the number of segments 
 
 
affected are summarized in figure 4. The distribution of the SAS is illustrated in figure 
5 and demonstrate a marked positive skew.  
 
Correlation of WBMRA results with risk factors 
The correlations between the SAS and the baseline demographic and risk factors 
were assessed by univariable analysis (Supplemental table S3). A significant 
correlation with SAS was present for age (ρ=0.25, p<0.001), systolic BP (ρ=0.11, 
p<0.001), total cholesterol (ρ=0.16, p<0.001), low density lipoprotein (LDL) (ρ=0.12, 
p<0.001), and the adult treatment panel III cardiovascular risk score for both the total 
population (ρ=0.15, p<0.001) and for males (ρ=0.28, p<0.001) and females (ρ=0.22, 
p<0.001) separately. Triglycerides showed a correlation for females only, while the 
Scottish Index of Multiple Deprivation (SIMD) showed a correlation when considered 
for the whole population, but not when analyzed for each individual gender. 
Linear multiple regression modelling demonstrated that age, heart rate, systolic BP, 
SIMD decile, ex-smoking status and current smoking status were independently 
associated with SAS (table 3).  
Because the SAS was very positively skewed further sensitivity analysis was 
performed examining both those with a SAS above and below the 80th percentile and 
the number of stenosed vessels rather than the SAS score.  The baseline 
characteristics of those with a SAS above the 80th percentile are compared with 
those below the 80th percentile in supplemental table S4. Men and women with an 
SAS above the 80th percentile were older, had a higher systolic BP and had a higher 
predicted CHD risk when compared to those with an SAS below the 80th percentile. 
Additionally, men were more likely to be current or ex-smokers and women had a 
higher total and LDL cholesterol and higher triglycerides. If, rather than using the 
 
 
SAS, the number of stenosed vessels was used, or the population was split into 
those with and without any vascular stenosis, similar results were seen 
demonstrating the robustness of the observations. (Supplemental tables S5 and S6).  
 
Discussion 
Our study shows that within a population considered to be at low-intermediate risk of 
CVD, that while on a per vessel basis disease prevalence is low at 5.3%, 49.4% of 
participants 49.4% of participants have at least one vessel with stenotic disease and 
27% have multi-vessel disease. This disease is relatively evenly distributed 
throughout the cardiovascular system. 
There was a high technical success rate with only 15 of the 1528 studies (1%) being 
considered non-diagnostic, demonstrating the aptitude of the technique for more 
widespread use. Our finding that both the atheroma burden and number of stenotic 
vessels correlated with age, BP, cholesterol and cardiovascular risk is perhaps 
unsurprising as these are all risk factors for cardiovascular events (24). We 
demonstrate a significant association between the global atheroma burden and 
socioeconomic deprivation, which is in keeping with prior observations of 
socioeconomic deprivation being a marker of cardiovascular risk (25).  Similar 
associations between socioeconomic status and CIMT have been described in 
adulthood as well as in children as young as 10, with the exact causative mechanism 
under debate but is most likely an interplay of stress, second hand smoke and 
diet.(26,27) These findings provide validation of the atheroma score for the detection 
of subclinical atherosclerosis in a population not considered to be at high risk for 
cardiovascular events. Our prevalence of atherosclerotic changes of 49.4% is much 
lower than the 68% in the PIVUS study (18), however this previous study included 
 
 
those with known cardiovascular disease and focussed on an older cohort, only 
recruiting 70 year olds. In contrast, our rates are much higher than the 21% 
prevalence of vascular disease seen in a previous study in 298 healthy study 
participants using a variant of the whole-body technique. However, the authors of 
this previous study only looked for atherosclerotic disease causing greater than 50% 
stenosis, ignoring lower grade stenoses (7).  
While the vast majority of arterial segments in the WBMRAs were normal, almost 
50% of the population exhibited pre-clinical stenotic disease, with more than 25% 
exhibiting multifocal disease. For our study, of the vessels affected by early 
atherosclerosis, the most common sites detected were the abdominal aorta and iliac 
arteries. This is of particular interest as both areas are poorly evaluated with current 
imaging strategies such as coronary calcium scoring or CIMT measurement.  
While we have demonstrated the ability of WBMRA to detect extensive subclinical 
disease, the clinical importance of this is yet to be established, as is the best method 
for quantifying the extent of atherosclerosis. The PIVUS study showed that the 
atheroma score was the strongest predictor of major adverse cardiovascular events 
at 5 years, and improved discrimination and reclassification when added to the 
Framingham Risk Score, with superior predictive value to CIMT and ankle-brachial 
pressure index (14). However, the authors did not compare this with the number of 
diseased vessels. A previous study in those with diabetes mellitus demonstrated that 
both the atheroma score and the number of diseased vessels conferred prognostic 
benefits over traditional cardiovascular risk markers (15). Long term follow-up at 5, 
10 and 15 years is planned in our TASCFORCE study and will allow us to determine 
if these observations hold true in a low-intermediate risk cohort, and will also allow 
comparison of the different metrics of quantifying atheroma development and 
 
 
distribution to determine whether it is certain vessels, a combination of vessels or a 
global summation of disease burden that are the best markers of cardiovascular risk. 
Determination of a particular risk profile of high risk sites may help target other 
cheaper, more accessible modalities to the relevant vessels, increasing the 
prognostic yield of these. 
Our study has several limitations. WBMRA is a lumenographic technique, thus 
potentially missing early vascular changes where there is positive remodeling. There 
are several promising MR imaging techniques for wall thickening and early fatty 
streak deposition detection (28); yet to date these have only been applied in singular 
vascular territories with the inherent weaknesses of this as discussed above. In 
addition the coronary arteries were not assessed.  Atheroma burden on WBMRA has 
previously been demonstrated to correlate well with the presence of obstructive 
coronary artery disease (29), thus our current results would suggest there was 
substantial undetected disease within the coronary circulation as well.  At the time of 
our study design, MR coronary angiography was in its infancy, being time 
consuming, technically challenging, and of limited accuracy; however, recent 
advances mean it may be incorporated into future whole body angiography.  It will be 
worthwhile to examine the additional disease burden and the prognostic value that 
this could yield (30). 
In conclusion, WBMRA identifies early vascular disease at a population level, and 
the systematic nature of its evaluation allows it to detect early atherosclerotic 
disease missed by modalities that only assess single vascular sites.  
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Table 1: Coding and scoring for WBMRA arterial segments. 
Abnormality Code  Score*  
Normal 0 0 
<50% stenosis 1 1 
51-70% stenosis 2 2 
71-99% stenosis 3 3 
Occluded segment 4 4 
Aneurysm but no stenosis 5 1 
Aneurysm and <50% stenosis 6 2 
Aneurysm and 51-70% stenosis 7 3 
Aneurysm and 71-99% stenosis 8 4 
Aneurysm and occlusion 9 5 
 
The aneurysmal and stenotic status were coded and scored according to the severity 
of the stenosis. *Score ascribed to contribute to whole body atheroma score. 
WBMRA=whole body magnetic resonance angiography. 
 
 
  
 
 
Table 2: Characteristics of those who had an MR imaging scan and those who 
declined or were unable to complete a scan 
Variable Underwent MR 
imaging scan 
(n=1528) 
Unable/declined 
to have MR 
imaging scan 
(n=539) 
*p 
value 
No (%) men 579 (37.9) 233 (43.3) 0.03 
Median (IQR) age (years) 53.5 (12.2) 52.6 (13.3) 0.57 
No (%) current smokers 165 (10.8) 57 (10.6) 0.88 
No (%) former smokers 417 (27.3) 150 (27.9) 0.81 
No (%) never smoked 940 (61.5) 330 (61.3) 0.90 
Mean (SD) systolic 
BP(mmHg)   
122.4 (12.1) 123.7 (11.7) 0.046 
Mean (SD) diastolic 
BP(mmHg)   
72.8 (9.2) 73.8 (9.3) 0.02 
Median (IQR) heart rate 
(beats per min) 
62 (12) 64 (11) <0.00
1 
Mean (SD) total cholesterol 
(mmol/l) 
5.51 (0.96) 5.51 (1.02) 0.89 
Mean (SD) high density 
lipoprotein (mmol/l)  
1.43 (0.42) 1.38 (0.39) 0.04 
Mean (SD) low density 
lipoprotein (mmol/l) 
3.39 (0.87) 3.41 (0.93) 0.78 
Median (IQR) triglycerides 
(mmol/l) 
1.33 (0.98) 1.41 (0.98) 0.09 
 
 
Median (IQR) body mass 
index 
26.1 (5.3) 26.3 (6.0) 0.15 
Mean (SD) waist 
circumference (cm) 
86.0 (16.0) 87.0 (17.0) 0.10 
Median (IQR) CHD risk score 2 (5) 3 (5) 0.19 
Median (IQR) ASSIGN score 7.4 (7.9) 7.8 (8.8) 0.18 
Number (%) with family 
history of CV disease 
392 (25.7) 128 (23.8) 0.39 
SIMD Number (%) 1 65 (4.3) 23 (4.3) 0.14 
 2 79 (5.2) 29 (5.4) 
 3 101 (6.6) 50 (9.3) 
 4 77 (5.0) 39 (7.2) 
 5 95 (6.2) 31 (5.8) 
 6 167 (10.9) 40 (7.4) 
 7 248 (16.2) 91 (16.9) 
 8 297 (19.4) 107 (19.9) 
 9 279 (18.3) 92 (17.1) 
 10 117 (7.7) 35 (6.5) 
 
MR=magnetic resonance, IQR=inter-quartile range, SD=standard deviation, 
BP=blood pressure, CHD=coronary artery disease, ASSIGN=Assessing 
cardiovascular risk using Scottish Intercollegiate Guideline Network, 
CV=cardiovascular, SIMD=Scottish Index of Multiple Deprivation.  
 
 
*Unpaired t-test was used for normally distributed variables, Mann-Whitney test for 
skewed and ranked variables and Chi-square test for binomial variables. SIMD was 
treated as a continuous variable for the purpose of analysis. 
  
 
 
Table 3: Multivariable analysis of traditional cardiovascular risk factors, socio-
demographic factors and BNP in relation to standardized atheroma score 
Risk Factor B coefficient (95% CI) P 
log age (years) 3.40 (2.61,4.20) <0.001 
log heart rate (bpm) 1.23 (0.51,1.95) <0.001 
log triglycerides (mmol/l) 0.24 (-0.39,0.87) NS 
log BMI (kg/m2) -0.26 (-1.46,0.93) NS 
log BNP (pg/ml) 0.15 (-0.08,0.38) NS 
Systolic BP (mmHg) 0.02 (0.01,0.03) <0.001 
Diastolic BP (mmHg) -0.01 (-0.03,0.01) NS 
Total cholesterol (mmol/l) -0.12 (-0.95,0.70) NS 
HDL (mmol/l) -0.01 (-0.87,0.86) NS 
LDL (mmol/l) 0.23 (-0.59,1.04) NS 
Waist circumference (cm) -0.01 (-0.02,0.01) NS 
SIMD Decile -0.06 (-0.10,-0.02) 0.005 
Male gender (compared to female) 0.05 (-0.25,0.36) NS 
Ex-smoker (v never smoked) 0.35 (0.10,0.60) 0.009 
Current smoking (v never smoked) 0.79 (0.44,1.15) 0.004 
Family history of CVD (v no family 
history) 
0.24 (-0.01,0.49) 
NS 
Proportion of variability explained 
by model§ 
11.4% <0.001 
 
§Proportion of variability (adjusted r2) explained by the cardiovascular, demographic 
and blood markers included in model. CI=confidence interval, bpm=beats per 
minute, BMI=body mass index, BNP=brain natriuretic peptide, BP=blood pressure, 
 
 
HDL=high density lipoprotein, LDL=low density lipoprotein, SIMD= Scottish Index of 
Multiple Deprivation, CVD=cardiovascular disease. 
  
 
 
Figure 1  
Participant Flow Diagram of the TASCFORCE Study 
Diagram shows participant flow through the study. BNP=brain natriuretic peptide, 
CV=cardiovascular, MRI=magnetic resonance imaging, WBMRA=whole body 
magnetic resonance angiography. 
 
Figure 2 
Examples of whole body angiograms  
Normal study with no disease evident in a 45yo woman (A). Evidence of extensive 
disease including left carotid bulb stenosis (open arrow head), bilateral renal artery 
stenosis (closed arrow heads) and an occluded right superficial femoral artery 
(triangle) in a 53yo woman (B). 
 
Figure 3 
Distribution of abnormalities at arterial segment level 
The graph shows the incidence of stenoses according to the grade, and of 
aneurysm.  
Total 1= less than 50% stenosis, total 2= 51-70% stenosis, total 3=71-99% stenosis, 
total 4= occlusion, total >4=presence of aneurysm with or without stenosis. L=left, 
R=right, ICA=internal carotid artery, VA=vertebral artery, IN AR=innominate artery, 
CCA=common carotid artery, SC=subclavian artery, AOR A=aortic arch, THOR 
AO=thoracic aorta, ABD AO=abdominal aorta, COEL=celiac trunk, SMA=superior 
mesenteric artery, IMA=inferior mesenteric artery, REN=renal artery, ILIAC=iliac 
 
 
artery, FEM=femoral artery, PROF=profunda femoris artery, POP=popliteal artery, 
AT=anterior tibial artery, PER=peroneal artery, PT=posterior tibial artery. 
 
Figure 4 
Frequency of stenotic disease  
Incidence of stenotic disease according to the number of segments involved, per 
participant (celiac trunk excluded). 
 
Figure 5  
Standardized atheroma score distribution 
Distribution of the standardized atheroma scores in the population (celiac trunk 
excluded). 
 
  
 
 
Supplemental table 1: Summary of MR imaging incidental findings requiring 
clinical review and/or further investigation 
Nature of finding Frequency 
Myocardial infarct detected by delayed enhancement 3 
Structural cardiac abnormality 7 
Benign mass 10 
Malignant mass 1 
Peripheral arterial abnormality 6 
Anatomical variant/malformation 5 
Other finding 2 
 
 
  
 
 
Supplemental table 2: Activity arising as a result of MR imaging incidental 
findings 
Activity Number of participants 
Investigations  
Abdominal/pelvic ultrasound scan 7 
Vascular ultrasound scan 2 
Plain x-ray 1 
Echocardiogram 6 
Other investigation* 3 
Review  
Review by study doctor 6 
Review by General Practitioner 9 
Referral and review to hospital specialist 17 
Intervention by study team  
Medication started on advice of study doctor 2 
*Other investigations include exercise tolerance tests, blood tests. 
 
  
 
 
Supplemental table 3: Univariable analysis of correlations between baseline 
factors and standardized atheroma score 
Variable 
Association with SAS 
Entire 
population 
(n=1513) 
Men 
(n=577) 
Women 
(n=936) 
Age (years) 
0.25 (<0.001) 0.28 (<0.001) 0.23 (<0.001) 
Systolic BP (mmHg) 
0.11 (<0.001) 0.10 (0.02) 0.13 (<0.001) 
Diastolic BP (mmHg) 0.03 (0.19) 0.04 (0.29) 0.04 (0.20) 
Heart rate (beats/min) 0.05 (0.05) 0.02 (0.64) 0.06 (0.06) 
Total cholesterol (mmol/l) 
0.16 (<0.001) 0.13 (0.002) 0.17 (<0.001) 
HDL (mmol/l) 0.03 (0.28) 0.00 (0.93) 0.02 (0.49) 
LDL (mmol/l) 
0.12 (<0.001) 0.10 (0.026) 0.14 (<0.001) 
Triglycerides (mmol/l) 
0.06 (0.018) 
0.05 (0.20) 
0.09 (0.007) 
BMI (kg/m2) -0.03 (0.26) 0.00 (0.92) -0.03 (0.31) 
Waist circumference (cm) -0.02 (0.43) 0.05 (0.21) -0.02 (0.47) 
SIMD 
-0.08 (0.005) 
-0.08 (0.06) -0.01 (0.67) 
Predicted CHD risk score 
using ATPIII algorithm 
(%/10 years) 
0.15 (<0.001) 0.28 (<0.001) 0.22 (<0.001) 
BNP (pg/ml) 0.03 (0.20) 0.06 (0.13) -0.02 (0.64) 
 
Spearman rank correlation test is used. ρ and (p) values are given. 
SAS=standardized atheroma score, HDL=high density lipoprotein, LDL=low density 
lipoprotein, BP=blood pressure, BMI=body mass index, BNP=brain natriuretic 
peptide, SIMD=Scottish Index of Multiple Deprivation, CHD=coronary heart disease, 
ATPIII= adult treatment panel III. 
 
 
Supplemental table S4: Baseline variable comparison between those with 
standardised atheroma score greater and less than 80th centile 
Variable 
Total population Men Women 
<80th 
centile 
SAS 
(n=12
78) 
>80th 
centile 
SAS 
(n=23
5) 
p 
value 
<80th 
centile 
SAS 
(n=46
4) 
>80th 
centile 
SAS 
(n=11
3) 
p 
value 
<80th 
centile 
SAS 
(n=78
6) 
>80th 
centile 
SAS 
(n=15
0) 
p 
value 
Median 
(IQR) age 
(years) 
52.3 
(11.8) 
58.9 
(12.1) 
<0.00
1 
51.8 
(10.8) 
59.9 
(10.8) 
<0.00
1 
53.4 
(8.2) 
58.8 
(8.2) 
<0.00
1 
No (%) 
current 
smokers 
125 
(9.8) 
40 
(17.0) 
0.001 32 
(6.9) 
19 
(16.8) 
0.001 90 
(11.5) 
24 
(16.0) 
0.12 
No (%) 
former 
smokers 
332 
(26.0) 
78 
(33.2) 
0.022 118 
(25.4) 
45 
(39.8) 
0.003 205 
(26.1) 
42 
(28.0) 
0.61 
No (%) 
never 
smokers 
816 
(63.8) 
116 
(49.4) 
<0.00
1 
312 
(67.2) 
49 
(43.4) 
<0.00
1 
488 
(62.1) 
83 
(55.3) 
0.13 
Mean (SD) 
systolic BP 
(mmHg) 
122.0 
(12.1) 
125.3 
(12.1) 
<0.00
1 
124.6 
(11.0) 
127.2 
(10.5) 
0.022 120.2 
(12.4) 
124.3 
(12.7) 
<0.00
1 
Mean (SD) 
diastolic BP 
(mmHg) 
72.7 
(9.3) 
73.5 
(9.0) 
0.23 74.9 
(8.9) 
74.8 
(8.4) 
0.95 71.3 
(9.2) 
72.8 
(9.2) 
0.08 
Median 
(IQR) heart 
rate 
(beats/min) 
62 
(12) 
63 
(13) 
0.40 60 
(11) 
60  
(14) 
0.73 65  
(10) 
65  
(9) 
0.55 
Mean (SD) 
total 
cholesterol 
(mmol/l) 
5.43 
(0.97) 
5.71 
(0.94) 
<0.00
1 
5.38 
(0.94) 
5.52 
(0.78) 
0.12 5.46 
(1.02) 
5.81 
(1.02) 
<0.00
1 
Mean (SD) 
HDL 
(mmol/l) 
1.44 
(0.42) 
1.47 
(0.44) 
0.35 1.24 
(0.39) 
1.28 
(0.38) 
0.39 1.56 
(0.40) 
1.56 
(0.44) 
0.98 
 
 
Mean (SD) 
LDL (mmol/l) 
3.36 
(0.88) 
3.56 
(0.84) 
0.001 3.38 
(0.85) 
3.50 
(0.75) 
0.15 3.34 
(0.90) 
3.59 
(0.89) 
0.002 
Median 
(IQR) 
triglycerides 
(mmol/l)$ 
1.26 
(1.00) 
1.36 
(1.01) 
0.043 1.50 
(1.22) 
1.60 
(1.19) 
0.95 1.11 
(0.84) 
1.26 
(0.92) 
0.002 
Median 
(IQR) BMI 
(kg/m2) $ 
26.2 
(5.2) 
26.0 
(5.4) 
0.50 26.7 
(4.41) 
26.3 
(5.19) 
0.59 25.6 
(5.5) 
25.8 
(5.5) 
0.89 
Median (SD) 
waist 
circumferenc
e (cm) 
86.6 
(13.1) 
86.6 
(11.9) 
0.99 92.0 
(14.0) 
93.0 
(14.6) 
0.72 81.0 
(15.0) 
82.3 
(15.0) 
0.55 
Median 
(IQR) 
predicted 
CHD risk 
score using 
ATPIII 
algorithm 
(%/10 years) 
$ 
2 (5) 4 (9) <0.00
1 
6 (6) 10 (5) <0.00
1 
1 (2) 2 (3) <0.00
1 
Median 
(IQR) BNP 
(pg/ml) $ 
22.6 
(15.0) 
23.3 
(18.4) 
0.19 15.3 
(12.0) 
16.6 
(12.3) 
0.07 26.5 
(17.3) 
26.6 
(19.6) 
0.90 
No (%) with 
family 
history of CV 
disease 
323 
(25.3) 
66 
(28.1) 
0.37 108 
(23.3) 
25 0.79 209 
(26.6) 
47 
(31.3) 
0.23 
SIMD, 
Number 
(%) 
1 48 
(3.8) 
17 
(7.2) 
0.10 12 
(2.6) 
8 (7.1) 0.31 35 
(4.5) 
10 
(6.7) 
0.41 
2 
66 
(5.2) 
13 
(5.5) 
21 
(4.5) 
4 (3.5) 44 
(5.6) 
10 
(6.7) 
3 
80 
(6.3) 
21 
(8.9) 
26 
(5.6) 
10 
(8.8) 
51 
(6.5) 
14 
(9.3) 
4 
66 
(5.2) 
10 
(4.3) 
28 
(6.0) 
6 (5.3) 37 
(4.7) 
5 (3.3) 
5 
80 
(6.3) 
15 
(6.4) 
29 
(6.3) 
6 (5.3) 51 
(6.5) 
9 (6.0) 
 
 
6 
143 
(11.2) 
20 
(8.5) 
52 
(11.2) 
13 
(11.5) 
86 
(10.9) 
12 
(8.0) 
7 
202 
(15.8) 
45 
(19.1) 
67 
(14.4) 
21 
(18.6) 
126 
(16.0) 
33 
(22.0) 
8 
254 
(19.9) 
40 
(17.0) 
98 
(21.1) 
18 
(15.9) 
155 
(19.7) 
23 
(15.3) 
9 
231 
(18.1) 
43 
(18.3) 
88 
(19.0) 
20 
(17.7) 
140 
(17.8) 
26 
(17.3) 
10 
105 
(8.2) 
11 
(4.7) 
43 
(9.3) 
7 (6.2) 58 
(7.4) 
8 (5.3) 
Unpaired t-test used to compare means for variables with a normal distribution. 
Mann-Whitney test used for variables with a skewed distribution (indicated by $). 
SAS=standardised atheroma score, IQR=interquartile range, SD=standard deviation, 
HDL=high density lipoprotein, LDL=low density lipoprotein, BMI=body mass index, 
CHD=coronary heart disease, ATPIII= Adult Treatment Panel III, BNP= B-type 
natriuretic peptide, CV=cardiovascular, SIMD=Scottish index of multiple deprivation. 
 
  
 
 
Supplemental table S5: Univariable correlations between percentage of arterial 
segments with any degree of stenosis or aneurysm and baseline risk factors 
Variable Association with percentage of vessels affected by 
stenosis and/or aneurysm 
Entire 
population 
(n=1513) 
Men 
(n=577) 
Women 
(n=936) 
Age (years) 0.26 (<0.001) 0.29 (<0.001) 0.24 (<0.001) 
Systolic BP (mmHg) 0.11 (<0.001) 0.10 (0.020) 0.14 (<0.001) 
Diastolic BP (mmHg) 0.04 (0.17) 0.03 (0.43) 0.05 (0.13) 
Heart rate (beats/min) 0.05 (0.041) 0.02 (0.67) 0.07 (0.043) 
Total cholesterol (mmol/l) 0.16 (<0.001) 0.13 (0.001) 0.18 (<0.001) 
HDL (mmol/l) 0.03 (0.20) 0.01 (0.82) 0.03 (0.38) 
LDL (mmol/l) 0.13 (<0.001) 0.10 (0.027) 0.15 (<0.001) 
Triglycerides (mmol/l) 0.06 (0.012) 0.06 (0.13) 0.09 (0.006) 
BMI (kg/m2) -0.03 (0.30) 0.003 (0.94) -0.03 (0.32) 
Waist circumference (cm) -0.02 (0.52) 0.06 (0.16) -0.02 (0.50) 
SIMD -0.04 (0.11) -0.08 (0.07) -0.02 (0.58) 
Predicted CHD risk score 
using ATPIII algorithm 
(%/10 years) 
0.15 (<0.001) 0.29 (<0.001) 0.22 (<0.001) 
BNP (pg/ml) 0.04 (0.13) 0.07 (0.09) -0.01 (0.70) 
 
Spearman rank correlation test is used. ρ and (p) values are given. BP=blood 
pressure, HDL=high density lipoprotein, LDL=low density lipoprotein, BMI=body 
mass index, SIMD=Scottish index of multiple deprivation, CHD=coronary heart 
disease, ATPIII= Adult Treatment Panel III, BNP=B-type natriuretic peptide.  
 
 
 
 
 
  
 
 
Supplemental table S6: Comparison of baseline characteristics between those 
with no atheroma and those with any atheroma 
 Total population Men Women 
Variable No 
stenos
is 
(n=76
5) 
Any 
stenos
is 
(n=74
8) 
p 
value* 
No 
steno
sis 
(n=30
8) 
Any 
stenos
is 
(n=26
9) 
p 
value* 
No 
stenos
is 
(n=45
7) 
Any 
stenos
is 
(n=47
9) 
p 
value* 
Median (IQR) 
age (years) 
51.7 
(11.6) 
55.3 
(13.0) 
<0.001 51.5 
(10.3) 
55.6 
(13.5) 
<0.001 51.9 
(12.3) 
55.3 
(12.9) 
<0.001 
No (%) current 
smokers 
68 
(8.9) 
97 
(13.0) 
0.010 20 
(6.5) 
31 
(11.5) 
0.034 48 
(10.5) 
66 
(13.8) 
0.12 
No (%) former 
smokers 
199  
(26.0) 
211  
(28.2) 
0.32 76 
(24.7) 
87 
(32.3) 
0.041 123 
(26.9) 
124 
(25.9) 
0.75 
No (%) never 
smokers 
496  
(64.8) 
436  
(58.3) 
0.011 211  
(68.5) 
150  
(55.8) 
0.002 285 
(62.4) 
286 
(59.7) 
0.45 
Mean (SD) 
systolic 
BP(mmHg)   
121.6 
(12.3) 
123.4 
(11.9) 
0.006 124.6 
(11.3) 
125.8 
(10.5) 
0.17 119.7 
(12.5) 
122.0 
(12.4) 
0.005 
Mean (SD) 
diastolic 
BP(mmHg)   
72.6  
(9.4) 
73.0  
(9.0) 
0.36 74.5 
(9.1) 
75.2  
(8.5) 
0.36 71.3  
(9.4) 
71.8  
(9.0) 
0.38 
Median (IQR) 
heart rate 
(bpm) 
61 
(11) 
63 
(11) 
0.08 60 
(12) 
61 
(12) 
0.51 63 
(10) 
64 
(12) 
0.14 
Mean (SD) 
total 
cholesterol 
(mmol/L) 
5.33 
(0.93) 
5.62 
(1.00) 
<0.001 5.31 
(0.91) 
5.52 
(0.91) 
0.006 5.35 
(0.94) 
5.67 
(1.04) 
<0.001 
Mean (SD) 
high density 
lipoprotein 
(mmol/l) 
1.43 
(0.42) 
1.45 
(0.43) 
0.25 1.26 
(0.39) 
1.24 
(0.38) 
0.61 1.54 
(0.40) 
1.57 
(0.41) 
0.27 
 
 
Mean (SD) low 
density 
lipoprotein 
(mmol/l) 
3.28 
(0.85) 
3.49 
(0.89) 
<0.001 3.33 
(0.84) 
3.48 
(0.82) 
0.040 3.25 
(0.85) 
3.51 
(0.93) 
<0.001 
Median (IQR) 
triglycerides 
(mmol/l) 
1.25 
(1.00) 
1.30 
(1.02) 
0.12 1.48 
(1.19) 
1.60 
(1.24) 
0.15 1.11 
(0.86) 
1.17 
(0.86) 
0.15 
Median (IQR) 
body mass 
index (kg/m2) 
26.4  
(5.3) 
26.0  
(5.1) 
0.16 26.7  
(4.3) 
26.7  
(4.7) 
0.80 25.7  
(6.0) 
25.5  
(5.4) 
0.10 
Mean (SD) 
waist 
circumference 
(cm) 
86.9 
(13.2) 
86.3 
(12.6) 
0.40 92.0 
(11.8) 
93.3 
(11.0) 
0.17 83.4 
(13.0) 
82.4 
(11.7) 
0.21 
Median (IQR) 
10 year CHD 
risk estimation 
(%) 
2 (4) 2 (5) <0.001 6 (6) 8 (7) <0.001 1 (2) 1↑ (2) <0.001 
No (%) with 
family history 
of CV disease 
188  
(24.6) 
201  
(26.9) 
0.31 69 
(22.4) 
64 
(23.8) 
0.69 119  
(26.0) 
137  
(28.6) 
0.38 
SIMD, 
Number 
(%) 
1 31 
(4.1) 
34 
(4.5) 
0.65 8 (2.6) 12 
(4.5) 
0.31 23 
(5.0) 
22 
(4.6) 
0.87 
2 37 
(4.8) 
42 
(5.6) 
12 
(3.9) 
13 
(4.8) 
25 
(5.5) 
29 
(6.1) 
3 55 
(7.2) 
46 
(6.1) 
20 
(6.5) 
16 
(5.9) 
35 
(7.7) 
30 
(6.3) 
4 37 
(4.8) 
39 
(5.2) 
18 
(5.8) 
16 
(5.9) 
19 
(4.2) 
23 
(4.8) 
5 46 
(6.0) 
49 
(6.6) 
19 
(6.2) 
16 
(5.9) 
27 
(5.9) 
33 
(6.9) 
6 90 
(11.8) 
73 
(9.8) 
38 
(12.3) 
27 
(10.0) 
52 
(11.4) 
46 
(9.6) 
7 113 
(14.8) 
134 
(17.9) 
36  
(11.7) 
52  
(19.3) 
77  
(16.8) 
82  
(17.1) 
8 151 
(19.7) 
143 
(19.1) 
63 
(20.5) 
53 
(19.7) 
88 
(19.3) 
90 
(18.8) 
9 145 
(19.0) 
129 
(17.2) 
63 
(20.5) 
45 
(16.7) 
82 
(17.9) 
84 
(17.5) 
10 57 59 31 19 26 40 
 
 
(7.5) (7.9) (10.1) (7.1) (5.7) (8.4) 
 
*Unpaired t-test was used for normally distributed variables, Mann-Whitney test for 
skewed and ranked variables and Chi-square test for categorical variables. SIMD 
was treated as a continuous variable for the purpose of analysis. IQR=inter-quartile 
range, SD=standard deviation, BP=blood pressure, bpm=beats per minute, 
CHD=coronary heart disease, CV=cardiovascular, SIMD=Scottish Index of Multiple 
Deprivation. 
 
